SCHEDULE: Baker Bros. Boosts Kodiak Sciences Stake to 32.8% After Offering

Baker Bros. Advisors and its affiliates increased their beneficial ownership in Kodiak Sciences Inc. to 32.8% following participation in a recent public offering.

Summary

• Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, and Felix J. Baker (Reporting Persons) filed Amendment No. 11 to their Schedule 13D for Kodiak Sciences Inc.
• The amendment reports an increase in their beneficial ownership of Kodiak Sciences Inc. common stock.
• Kodiak Sciences Inc. completed a public offering of 6,956,522 shares of common stock at $23.00 per share, with underwriters fully exercising an option for an additional 1,043,478 shares, totaling 8,000,000 shares offered.
• Baker Bros. affiliated funds, 667, L.P. and Baker Brothers Life Sciences, L.P., collectively purchased 2,608,696 shares in this offering at $23.00 per share, investing approximately $60 million.
• Following these transactions, the Reporting Persons beneficially own an aggregate of 20,067,542 shares of Kodiak Sciences Inc. common stock, representing 32.8% of the class outstanding.
• Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC, serves on Kodiak's Board of Directors, chairs the Compensation Committee, and serves on the Nominating/Governance Committee.
• Felix J. Baker holds 148,356 vested non-qualified stock options with various exercise prices and expiry dates, and 40,000 unvested stock options granted on June 30, 2025, vesting on the earlier of June 30, 2026, or one day prior to the next annual meeting.
• Felix J. Baker entered into a lock-up agreement from December 16, 2025, to January 30, 2026, restricting the sale or transfer of his shares.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The company successfully raised significant capital through a public offering, which strengthens its financial position. The substantial participation and increased beneficial ownership by a major institutional investor like Baker Bros. Advisors signal strong confidence in Kodiak Sciences Inc.'s future prospects, despite the dilution for existing shareholders.

Positives

• Significant capital infusion for Kodiak Sciences Inc. through the public offering, strengthening its financial position.
• Strong vote of confidence from a major institutional investor, Baker Bros. Advisors, by increasing their stake and participating substantially in the public offering.
• Baker Bros. funds invested approximately $60 million in the offering, demonstrating continued commitment.

Negatives

• Dilution of existing shareholders' ownership percentage due to the issuance of 8,000,000 new shares in the public offering.

Risks

• Reporting Persons may purchase additional securities or dispose of existing securities in varying amounts and at varying times, which could impact the stock price.
• The Reporting Persons may discuss items of mutual interest with the Issuer's management and Board, potentially influencing corporate decisions.

Future Outlook

Reporting Persons may, in the ordinary course of business, purchase additional securities or dispose of securities in varying amounts and at varying times based on their ongoing assessment of factors such as the Issuer's business prospects, economic conditions, and market conditions. They may also engage in discussions with the Issuer's management and Board regarding financing or other strategic matters.

Management Comments

• The Funds hold securities of the Issuer for investment purposes.
• The policy of the Funds and the Adviser does not permit managing members of the Adviser GP to receive compensation for serving as directors of the Issuer, and the Funds are instead entitled to the pecuniary interest in any compensation received for their service.

Industry Context

This filing reflects a common practice in the biotechnology sector where companies, particularly those in clinical development, frequently raise capital through public offerings to fund research, development, and operational expenses. The significant participation of a specialized biotech investor like Baker Bros. Advisors in such an offering often signals continued confidence in the company's long-term potential, despite the inherent risks of drug development.

Corporate Governance

Related Party Transactions

• Baker Bros. affiliated funds (667, L.P. and Baker Brothers Life Sciences, L.P.) purchased 2,608,696 shares in Kodiak Sciences Inc.'s public offering. Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC, serves on Kodiak's Board of Directors. This constitutes a related party transaction where a significant shareholder, through its affiliates, participated in a capital raise by a company where its principal serves as a director.

Stakeholder Impact

• Shareholders: Experience dilution from the public offering but benefit from the company's strengthened financial position and the strong vote of confidence from a major institutional investor.
• Company (Kodiak Sciences Inc.): Receives substantial capital to fund operations and strategic initiatives.
• Baker Bros. Advisors: Increases its strategic stake in Kodiak Sciences Inc., reinforcing its influence and potential returns.

Next Steps

• Reporting Persons may continue to monitor their investment and potentially adjust their holdings in Kodiak Sciences Inc.
• Felix J. Baker's unvested stock options are expected to vest on the earlier of June 30, 2026, or one day prior to the next annual meeting of the Issuer's stockholders.
• The lock-up period for Felix J. Baker's shares will expire on January 30, 2026.

Key Dates

Recommendation

The filing indicates a significant capital raise for Kodiak Sciences Inc. and a substantial increase in beneficial ownership by a major institutional investor, Baker Bros. Advisors. This demonstrates strong institutional confidence in the company's prospects, which is generally a positive signal. However, the offering also results in dilution for existing shareholders. Without further financial performance data or specific strategic updates beyond the capital raise, a 'hold' recommendation is prudent, acknowledging the positive signal of institutional backing while awaiting more comprehensive operational and financial results to assess the long-term impact of the capital infusion.

Keywords

Kodiak Sciences, Baker Bros. Advisors, Schedule 13D, Public Offering, Common Stock, Beneficial Ownership, Institutional Investment, Biotech, Capital Raise, Equity Offering, KOD